The Therapeutic Effect of GPR81 in Autoimmune Hepatitis and Hepatocellular Carcinoma via Regulating the Immune Response
International Journal of Molecular Sciences · 30.06.2025 · 26 (13) · 6308
DOI: 10.3390/ijms26136308 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.06.2025. Verfasst von Yongmei Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Histology and Embryology, Center for Tissues Stem Cell and Translational Medicine Research, Key Laboratory of Regenerative Medici…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Receptors, G-Protein-Coupled, Liver Neoplasms, Hepatitis, Autoimmune. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Laboratory for Research on Autoimmune Diseases of Higher Education schools in Guizhou Province, The project funded by China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Autoimmune hepatitis (AIH) is linked to an increased risk of hepatocellular carcinoma (HCC). However, the precise connection between the two remains unclear. GPR81, a G-protein-coupled receptor located on the membranes of various cell types, plays a role in numerous physiological processes. We established an AIH animal model and activated GPR81 using the agonist 3,5-dihydroxybenzoic acid (3,5-DHBA). Additionally, the effect of GPR81 inhibition on tumor and immune cell dynamics was examined using the HepG2, Hep3B, and Hepa1-6 cell lines with the antagonist 3-hydroxybutyric acid (3-OBA). Our results demonstrated that 3,5-DHBA treatment reduced T cell and pro-inflammatory cytokine secretion, while MDSC secretion increased, inhibiting Concanavalin A (Con A)-induced AIH. The inhibition of GPR81 by 3-OBA suppressed HCC cell proliferation and invasion, reduced tumor volume and weight, and downregulated PD-L1 expression. Furthermore, CTL and DC activity in the spleen and tumors increased, while MDSC activity decreased. This study confirms that GPR81 plays an important role in both inflammation and tumorigenesis, suggesting that GPR81 may serve as a bridge in the transformation of inflammation into cancer. Modulating GPR81 activity may provide a novel therapeutic strategy for hepatitis and cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Histology and Embryology, Center for Tissues Stem Cell and Translational Medicine Research, Key Laboratory of Regenerative Medicine in Guizhou Province, Guizhou Medical University, Guiyang 550025, Ch…
ORCID-Profile: Youbo Zhao
Förderung
- National Natural Science Foundation of China
- Key Laboratory for Research on Autoimmune Diseases of Higher Education schools in Guizhou Province
- The project funded by China Postdoctoral Science Foundation
- Guizhou Provincial Science and Technology Projects
- QianKeHe Basic
Zitieren
APA
Wu, Y., Song, W., Wu, X., He, J., Su, M., Hu, R., & Zhao, Y. (2025). The Therapeutic Effect of GPR81 in Autoimmune Hepatitis and Hepatocellular Carcinoma via Regulating the Immune Response. International Journal of Molecular Sciences, 26(13), 6308. https://doi.org/10.3390/ijms26136308
Vancouver
Wu Y, Song W, Wu X, He J, Su M, Hu R, et al. The Therapeutic Effect of GPR81 in Autoimmune Hepatitis and Hepatocellular Carcinoma via Regulating the Immune Response. International Journal of Molecular Sciences. 2025;26(13):6308. doi:10.3390/ijms26136308
BibTeX
@article{Wu2025,
author = {Wu, Yongmei and Song, Wenqian and Wu, Xuxian and He, Jing and Su, Min and Hu, Rong and Zhao, Youbo},
title = {The Therapeutic Effect of GPR81 in Autoimmune Hepatitis and Hepatocellular Carcinoma via Regulating the Immune Response},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {13},
pages = {6308},
doi = {10.3390/ijms26136308}
}
EUVIMED